Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The validation of two International Myeloma Staging Systems: R2-ISS and MASS

In this video, Guldane Cengiz Seval, MD, Ankara University School of Medicine, Ankara, Turkey, discusses updates made to the second revision of the International Staging System (R2-ISS) and the Mayo Additive Staging System (MASS), highlighting how the integration of 1q gain into these staging systems impacts the prognostication of patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.